Navigation Links
Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day

CHICAGO, Aug. 22, 2014 /PRNewswire/ -- Zacks Equity Research highlights Epizyme (Nasdaq: EPZM-Free Report) as the Bull of the Day and Panera (Nasdaq: PNRA-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD-Free Report), Sanofi (NYSE: SNY-Free Report) and Shire (Nasdaq: SHPG-Free Report).

Here is a synopsis of all five stocks:

Bull of the Day:

The biotech bull market is far from over due to several secular and macro drivers like an aging population, cash-rich "big pharma" facing patent cliffs forcing them to buy new drugs, and the incredible success of small companies doing innovative disease R&D.

One such small company making headlines lately is Epizyme (Nasdaq: EPZM-Free Report), a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs.

HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

Writing for this week, David Sobek summed up the pre-clinical data and early clinical observations from an ongoing Phase I trial...

"Epizyme reported the first clinical data on its blood cancer pipeline candidate EPZ-6438 at the ASH Lymphoma Biology Conference last week. The drug is designed to block a specific enzyme, EZH2, which when mutated, is involved in development of certain cancers, including forms of non-Hodgkins lymphoma (NHL).

Bear of the Day:

Some "fast casual" eateries seem to have growing appeal and profits, like Chipotle, and some are really struggling like Panera (Nasdaq: PNRA-Free Report). I actually like Panera a lot -- best oatmeal raisin cookies, and I am an aficionado here -- but the stock has been in a sharp decline since its peak in Q1 above $190 and there's a good reason for it: falling profits.

In the past 90 days, 13 analysts have lowered full-year 2014 EPS estimates from $6.88 to $6.68. That's not a severe drop. But it is part of a longer trend where those estimates were over $8 last year.

And 2015 earnings projections have come down over 7% from $7.71 to $7.15. 2015 had started out last year close to $10.

Additional content:

Amicus (FOLD) Soars on Drug Trial Results

Shares of Amicus Therapeutics (Nasdaq: FOLD-Free Report) soared 20.4% after the company announced positive data from its second phase III study (Study 012) on the oral small molecule chaperone migalastat HCl in Fabry patients with amenable mutations.

The phase III study is evaluating the use of oral migalastat to standard-of-care enzyme replacement therapies (ERTs) − Sanofi's (NYSE: SNY-Free Report) Fabrazyme and Shire's (Nasdaq: SHPG-Free Report) Replagal − for Fabry disease. Eighteen-month data from the phase III study revealed that migalastat successfully met both the primary endpoints of comparability to ERT on key measures of kidney function. Additionally, the candidate demonstrated low and stable plasma lyso-Gb3 levels in patients who switched from ERT to migalastat.

In April this year, Amicus had announced positive results from its first phase III study (Study 011) on migalastat. Shares at that time had gained over 20% on the news. Migalastat had shown a statistically significant reduction in kidney interstitial capillary GL-3 at month 12 as compared to placebo.

Amicus plans to submit the marketing application for migalastat next year. We are encouraged by the positive data on migalastat considering that it is one of the key candidates at Amicus. We believe that post approval the drug could capture ERT's market share which is valued at over $1 billion. Investor focus is expected to remain on migalastat going forward. 

Amicus, a biopharmaceutical company, currently carries a Zacks Rank #2 (Buy).

Get today's Zacks #1 Stock of the Day with your free subscription to Profit from the Pros newsletter:

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Click here to subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on EPZM - FREE

Get the full Report on PNRA - FREE

Get the full Report on FOLD - FREE

Get the full Report on SNY - FREE

Get the full Report on SHPG - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339 provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Logo -

SOURCE Zacks Investment Research, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
2. Epizyme, Inc. Announces Pricing of Initial Public Offering
3. Epizyme, Inc. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on July 31, 2013
4. Epizyme, Inc. to Present at Wedbush Securities Life Sciences Management Access Conference in August
5. Epizyme, Inc. to Present at Upcoming Conferences in September
6. Epizyme, Inc. Granted Notice of Allowance of Patent for EPZ-5676
7. Epizyme, Inc. to Present at Upcoming Conferences in November
8. Epizyme, Inc. to Present Pre-Clinical Data on DOT1L and EZH2 Inhibitor Programs at the 55th ASH Annual Meeting
9. Epizyme, Inc. to Present at 32nd Annual J.P. Morgan Healthcare Conference
10. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
(Date:11/24/2015)...  NuShield, Inc., an industry leader in LCD screen protection and glare-elimination technology, is providing a ... of their patient monitoring or electronic documentation system. ... ... ... A study in 2013 by the National ...
(Date:11/24/2015)... Pa. , Nov. 24, 2015  BioPlast ... for the medical research, clinical diagnostic and biotech ... a leading manufacturer of quality petri dishes. This ... offer clients a platform of products that are ... manufactured with the highest quality.  ...
(Date:11/24/2015)... LYON, France , November 24, 2015 ... Pharma the patent they co-own with Inserm, Poxel, CNRS, UCBL ... --> --> Hepatitis B ... more than 350 million people chronically infected worldwide, 20 to ... disease, cirrhosis and hepatocellular carcinoma. Despite the existence of an ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... The Trustees, Massachusetts’ largest conservation ... parking fees at several of their most popular properties, including Crane Beach in ... of REI’s Black Friday #OptOutside Campaign. The Trustees encourage families and friends to ...
(Date:11/24/2015)... ... November 24, 2015 , ... The ... to support their local poison centers through donations on Tuesday, Dec. 1, 2015. ... it “a day that inspires people to collaborate in improving their local communities ...
(Date:11/24/2015)... ... ... , LLC launched their Pro Vest, the latest version of their widely popular weight loss ... 10 hours. , The campaign, which will continue to run through Saturday, ... , The PRO Vest provides consumers with a less expensive, one-size fits all comfort option, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Healthy Aging Program have announced their endorsement of the Medical Fitness Network ... Fitness is proud to have the MFN as one of our endorsed organizations,” ...
(Date:11/24/2015)... IL (PRWEB) , ... November 24, 2015 , ... All her life, Don Peck’s mother ... Even her obituary said she might have been. After a 25-year search for information, ... voyager with whom she shared a last name. Turns out, it was Don’s father ...
Breaking Medicine News(10 mins):